Alan Glicklich, MD

Articles by Alan Glicklich, MD

NeuroVoices: Pam Conley and Alan Glicklich, MD, on NVG-2089’s Potential to Treat CIDP

ByMarco Meglio,Pamela Conley,Alan Glicklich, MD

July 23rd 2025

Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

ByPamela Conley,Alan Glicklich, MD

June 12th 2025

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Alan Glicklich, MD

Articles by Alan Glicklich, MD

NeuroVoices: Pam Conley and Alan Glicklich, MD, on NVG-2089’s Potential to Treat CIDP

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited

Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding

Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease

Key Diagnostic Pearls for NMOSD Recognition and Testing: Elena Grebenciucova, MD